Skip to main content
Article thumbnail
Location of Repository

Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction

By M.R. Zile, J.S. Gottdiener, S.J. Hetzel, J.J.V. McMurray, M. Komajda, R. McKelvie, C.F. Baicu, B.M. Massie and P.E. Carson


<p><b>Background:</b> The purpose of this study was to examine the prevalence of abnormalities in cardiac structure and function present in patients with heart failure and a preserved ejection fraction (HFPEF) and to determine whether these alterations in structure and function were associated with cardiovascular morbidity and mortality.</p>\ud \ud <p><b>Methods and Results:</b> The Irbesartan in HFPEF trial (I-PRESERVE) enrolled 4128 patients; echocardiographic determination of left ventricular (LV) volume, mass, left atrial (LA) size, systolic function, and diastolic function were made at baseline in 745 patients. The primary end point was death or protocol-specific cardiovascular hospitalization. A secondary end point was the composite of heart failure death or heart failure hospitalization. Associations between baseline structure and function and patient outcomes were examined using univariate and multivariable Cox proportional hazard analyses. In this substudy, LV hypertrophy or concentric remodeling was present in 59%, LA enlargement was present in 66%, and diastolic dysfunction was present in 69% of the patients. Multivariable analyses controlling for 7 clinical variables (including log N-terminal pro-B–type natriuretic peptide) indicated that increased LV mass, mass/volume ratio, and LA size were independently associated with an increased risk of both primary and heart failure events (all P&#60;0.05).</p>\ud \ud <p><b>Conclusions:</b> Left ventricular hypertrophy or concentric remodeling, LA enlargement, and diastolic dysfunction were present in the majority of patients with HFPEF. Left ventricular mass and LA size were independently associated with an increased risk of morbidity and mortality. The presence of structural remodeling and diastolic dysfunction may be useful additions to diagnostic criteria and provide important prognostic insights in patients with HFPEF.</p

Publisher: American Heart Association
Year: 2011
OAI identifier:
Provided by: Enlighten

Suggested articles


  1. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. doi
  2. (2012). al I-PRESERVE Echo Substudy 2501 at GLASGOW UNIV LIB on January 31,
  3. Association of newer diastolic function parameters with age in healthy subjects: a population-based study. doi
  4. (2000). Atrial Area Increased Left Atrial Area p<0.0001 Primary Endpoint Number at Risk, Increased LA Area:
  5. Aurigemma GP; Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. doi
  6. (2007). Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, doi
  7. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. doi
  8. (2006). Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. doi
  9. Contractility and ventricular systolic stiffening in hypertensive heart disease: insights into the pathogenesis of heart failure with preserved ejection fraction.
  10. Dahlo ¨f B, Devereux RB. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study). doi
  11. (2008). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure doi
  12. for the I-PRESERVE Investigators. The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) trial: rationale and design. doi
  13. for the Investigators of the CHARM Echocardiographic Substudy—CHARMES. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy–CHARMES. doi
  14. (2000). Grade 1: Number at Risk, Grade 2: Number at Risk, doi
  15. (2008). Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur doi
  16. (2007). How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. doi
  17. (2012). Downloaded from Study Group. Treatment of hypertension in patients 80 years of age or older. doi
  18. Le Jemtel TH; New York Heart Failure Consortium. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. doi
  19. Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons 65 years of age (the Cardiovascular Health Study). doi
  20. Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. doi
  21. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
  22. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE) trial. doi
  23. Myocardial structure and function differ in systolic and diastolic heart failure.
  24. on behalf of the ASCOT Investigators. Baseline Heart Rate, Antihypertensive Treatment, and Prevention of Cardiovascular Outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). doi
  25. on behalf of the ASCOT Investigators. Tissue Doppler E/E ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy. doi
  26. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure.
  27. Patterns of structural and functional remodeling of the left ventricle in chronic heart failure. doi
  28. (2003). Prevalence of left ventricular diastolic dysfunction in the community: results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J.
  29. (2005). Prog Cardiovasc Dis.
  30. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. doi
  31. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Am Soc Echocardiogr. doi
  32. Role of Left Ventricular Stiffness in Heart Failure With Normal Ejection Fraction. doi
  33. Systolic and diastolic heart failure in the community. doi
  34. Treatment of heart failure with normal ejection fraction: an inconvenient truth! doi
  35. Tscho ¨pe C. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. doi
  36. Zanchetti A; VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.